title: Acute renal failure associated with haematological malignancies: a review of 10 years experience.
abstract: Patients with ARF and haematological malignancy (excluding myeloma), presenting to a single unit over 10 years were analyzed to see if patients likely to benefit from intensive renal supportive therapy could be identified. 31 episodes of ARF were identified in 29 patients (mean age 51 +/- 2.9 yr): 19 were associated with acute leukaemia (13 AML, 6 ALL); 10 with lymphoma. Acute tubular necrosis (ATN) was identified as the cause of ARF in 26 cases, with sepsis (96%) and exposure to nephrotoxic drugs (88%), especially aminoglycosides, being the commonest precipitating factors. Toxic levels of the latter were commonly documented. Patient survival was 45%. Requirement for mechanical ventilation resulted in a universally fatal outcome; age greater than 55 yr and the presence of CNS symptoms or signs were also significantly associated with a poor outcome. Non-ATN causes (urate nephropathy or obstruction) carried a better prognosis. However, only 4 patients (14%) lived for more than 6 months following ARF. Thus, although a subgroup of patients more likely to benefit from treatment can be identified, the overall prognosis is poor and limited by that of the underlying disease. The potential benefit of avoiding nephrotoxic drugs, especially aminoglycosides, in these patients is highlighted by this study.
authors.affiliation: Department of Nephrology, Leicester General Hospital, U.K.
authors.forename: K P
authors.initials: KP
authors.lastname: Harris
authors.forename: J M
authors.initials: JM
authors.lastname: Hattersley
authors.forename: J
authors.initials: J
authors.lastname: Feehally
authors.forename: J
authors.initials: J
authors.lastname: Walls
mesh_terms: D058186:Acute Kidney Injury / Q000453:epidemiology / Q000209:etiology*; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000617:Aminoglycosides / Q000009:adverse effects / Q000627:therapeutic use; D003524:Cyclosporins / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007683:Kidney Tubular Necrosis, Acute / Q000150:complications / Q000209:etiology; D007951:Leukemia, Myeloid / Q000150:complications; D008223:Lymphoma / Q000150:complications; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications; D012189:Retrospective Studies; D012307:Risk Factors; D013752:Tetracycline / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000617:Aminoglycosides; D003524:Cyclosporins; D013752:Tetracycline